Acoramidis Rapidly Boosts sTTR in ATTR-CM

A study found that acoramidis treatment induces a rapid increase in serum transthyretin (sTTR) levels, which benefits patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The findings were presented at the annual meeting of the Heart Failure Association of the European Society of Cardiology (ESC Heart Failure 2025).

In this trial, the investigators analyzed sTTR levels at baseline, on day 28, during month 3, and subsequently, once every 3 months. They used descriptive statistics in the modified intention-to-treat population to assess percentage changes in serum TTR levels.

At the time of randomization in ATTRibute-CM, 59 study participants were categorized as having ATTRv-CM (39 receiving acoramidis,  20 receiving placebo), and 552 participants were categorized as having ATTRwt-CM (370 receiving acoramidis, 182 receiving placebo).

The findings showed that the average baseline sTTR levels were lower in participants who had ATTRv-CM (acoramidis group, 17.8 mg/dL; placebo group, 17.2 mg/dL) compared with those who had  ATTRwt-CM (acoramidis group, 23.6 mg/dL; placebo group, 24.3 mg/dL). Levels of sTTR increased rapidly from baseline to day 28 in acoramidis-treated participants in both ATTRv-CM and ATTRwt-CM subgroups and remained stable until month 30, the investigators noted.

Notably, the average sTTR levels increased from baseline with acoramidis at day 28 in both the ATTRv-CM and ATTRwt-CM subgroups and remained stable until Month 30.

Source:

ESC Heart Failure 2025.